Standard BioTools
LAB
72 hedge funds and large institutions have $138M invested in Standard BioTools in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 19 reducing their positions, and 9 closing their positions.
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
54% more capital invested
Capital invested by funds: $89.1M → $138M (+$48.5M)
9% more funds holding
Funds holding: 66 → 72 (+6)
1.18% more ownership
Funds ownership: 58.88% → 60.06% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
16% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 19
16% less call options, than puts
Call options by funds: $83K | Put options by funds: $99K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HBWM
Hollow Brook Wealth Management
Katonah,
New York
|
+$4.67M |
| 2 |
Morgan Stanley
New York
|
+$3.69M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.56M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.31M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$2.87M |
| 2 |
CP
Caligan Partners
New York
|
-$2.21M |
| 3 |
NIM
Needham Investment Management
New York
|
-$2.12M |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$1.55M |
| 5 |
D.E. Shaw & Co
New York
|
-$521K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Walleye Capital
New York
| – | -$39.6K | -20,535 | Closed |
|
77
Cerity Partners
New York
| – | -$24.3K | -12,588 | Closed |
|
|
HF
78
HRT Financial
New York
| – | -$22K | -11,877 | Closed |
|
|
FHA
79
First Horizon Advisors
Memphis,
Tennessee
| – | -$5.79K | -3,000 | Closed |
|
|
RP
80
Repertoire Partners
New York
| – | -$193 | -100 | Closed |
|
LAB Hedge Fund Activity: Q3 2023 in Review
72 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2023, worth a combined $138M — up 54% from $89.1M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LAB positions and 9 closed out — a net gain of 6 holders — while 16 added to existing stakes and 19 trimmed.
The largest buyer was Hollow Brook Wealth Management, opening a new position worth an estimated $4.67M. The largest seller was Boothbay Fund Management, cutting an estimated $2.87M.
- 72 institutional investors held Standard BioTools (LAB) as of Q3 2023, up from 66 in Q2 2023.
- Funds reported $138M of Standard BioTools stock for Q3 2023, up 54% quarter-over-quarter.
- 15 funds opened new Standard BioTools positions in Q3 2023 and 9 closed out, a net change of +6 holders.
- The largest Standard BioTools buyer in Q3 2023 was Hollow Brook Wealth Management, an estimated $4.67M added.
- The largest Standard BioTools seller in Q3 2023 was Boothbay Fund Management, an estimated $2.87M sold.
Based on aggregated 13F filings for Q3 2023.